influenza
virus
one
major
zoonot
pathogen
continu
caus
global
health
concern
due
high
propens
unpredict
genet
mutat
major
surfac
antigen
hemagglutinin
ha
neuramindas
antivir
vaccin
vital
combat
threat
influenza
epidem
pandem
howev
increas
usag
licens
antivir
result
global
emerg
amantadin
andor
oseltamivirresist
strain
influenza
viru
typic
exampl
includ
worldwid
spread
adamantin
resist
virus
sinc
oseltamivirresist
season
virus
sinc
adamantaneresist
pandem
virus
peramivirresist
virus
hand
season
influenza
vaccin
updat
annual
due
continu
antigen
drift
shift
otherwis
mismatch
vaccin
formul
natur
select
would
consider
limit
effect
influenza
vaccin
neutral
antibodi
tradit
thought
provid
protect
influenza
virus
nevertheless
effect
induc
vaccin
limit
emerg
mutant
virus
resist
antibodymedi
neutral
regard
quest
univers
influenza
vaccin
fuel
interest
broadli
reactiv
antibodi
addit
direct
viru
neutral
antibodydepend
cellmedi
cytotox
adcc
use
effector
arm
innat
adapt
immun
respons
elimin
target
cell
natur
killer
nk
cell
upon
trigger
specif
adcc
antibodi
mediat
clearanc
virusinfect
cell
nk
cell
receptor
recogn
fc
portion
antibodi
turn
bind
antigen
virusinfect
cell
interact
induc
degranul
nk
cell
releas
perforingranzym
well
secret
antivir
cytokin
tumor
necrosi
sinc
adcc
could
invok
protect
immun
respons
infect
broad
array
virus
adcc
antibodi
respons
incorpor
one
import
featur
potenti
univers
vaccin
candid
world
health
organ
notabl
multipl
compon
influenza
virus
known
induc
adcc
includ
viral
surfac
protein
ha
ectodomain
well
intern
protein
includ
np
glycoprotein
ha
consist
two
function
domain
immunodomin
globular
head
domain
conserv
stalk
domain
convent
neutral
antibodi
respons
influenza
viru
domin
antibodi
target
head
region
block
viru
receptorbind
site
compar
bulki
globular
ha
head
ha
stem
region
far
less
immunogen
antibodi
direct
domain
occur
rel
low
frequenc
howev
rare
class
neutral
antibodi
target
conserv
site
ha
stem
report
recent
might
shed
new
light
develop
univers
influenza
vaccin
previous
identifi
two
put
adcc
epitop
map
ha
head
pandem
influenza
viru
epitop
design
reveal
epitop
map
convalescentphas
plasma
igg
antibodi
six
human
subject
domin
highli
conserv
studi
dissect
function
two
adcc
epitop
vitro
lethal
mous
model
surprisingli
result
demonstr
adcc
respons
elicit
epitop
trigger
detriment
rather
protect
effect
influenza
viru
infect
antivir
efficaci
provid
stalkspecif
adcc
antibodi
confirm
data
rais
concern
side
effect
certain
ha
head
epitop
devis
univers
influenza
vaccin
regard
studi
suggest
delic
balanc
protect
immun
induct
adcc
maintain
import
consider
evalu
vaccin
safeti
cell
line
deriv
mous
lung
adenoma
maintain
medium
gibco
supplement
heatinactiv
fetal
bovin
serum
fb
uml
penicillin
streptomycin
ps
peripher
blood
mononuclear
cell
pbmc
prepar
ficollpaqu
separ
heparin
whole
blood
obtain
healthi
balbc
mice
week
old
prepar
adcc
target
cell
cell
transfect
ha
express
plasmid
base
cdna
fragment
influenza
viru
strain
ahong
specif
fulllength
ha
fragment
clone
mammalian
express
vector
plasmid
contain
mous
fc
gene
pandem
influenza
viru
strain
ahong
use
vitro
viru
infect
mouseadapt
version
ahong
propag
embryon
hen
egg
util
vivo
experi
virus
store
aliquot
titrat
standard
plaqu
assay
experi
live
virus
conduct
use
biosafeti
level
facil
describ
previous
balbc
femal
mice
week
old
kept
biosafeti
level
hous
given
access
standard
pellet
feed
water
ad
libitum
experiment
protocol
follow
standard
oper
procedur
biosafeti
level
anim
facil
approv
anim
ethic
committe
univers
hong
kong
vaccin
carri
immun
mice
ha
epitop
dna
prime
protein
boost
pb
use
neg
control
specifi
vaccin
scheme
list
tabl
prepar
dna
plasmid
either
fragment
clone
mammalian
express
vector
describ
ha
plasmid
construct
result
plasmid
dna
per
mice
use
dna
prime
mice
electropor
prepar
protein
vaccin
recombin
ha
fusion
protein
express
freestyl
transient
express
system
invitrogen
purifi
protein
affin
ge
healthcar
subsequ
protein
dialyz
concentr
vivaspin
centrifug
concentr
ge
healthcar
follow
protein
boost
intramuscular
rout
mous
receiv
protein
protein
boost
sera
obtain
day
postimmunun
viru
challeng
antibodi
titer
rais
ha
mous
sera
evalu
elisa
previous
describ
modif
mous
sera
collect
pbstreat
group
taken
background
control
immun
mice
micegroup
inocul
five
lethal
dose
mouseadapt
pandem
influenza
viru
intranas
rout
ie
pfumous
anim
surviv
bodi
weight
monitor
daili
day
viru
challeng
bodi
weight
loss
set
human
endpoint
three
mice
per
group
randomli
select
euthan
day
postchalleng
respect
mous
lung
collect
euthan
mice
half
lung
tissu
harvest
viru
titrat
rtqpcr
method
half
immedi
fix
pb
buffer
formaldehyd
histopatholog
analys
describ
previous
slide
examin
blind
manner
score
semiquantit
system
accord
rel
degre
inflamm
tissu
damag
inflamm
score
follow
inflamm
perivascular
cuff
inflammatori
cell
mild
inflamm
extend
throughout
lung
moder
inflamm
lung
sever
inflamm
involv
one
half
lung
antibodydepend
cellmedi
cytotox
activ
reflect
rate
cell
death
measur
flow
cytometrybas
assay
describ
previous
modif
gener
dye
sigma
util
label
target
cell
ie
hatransfect
cell
invitrogen
use
stain
dead
cell
mediat
adcc
activ
experiment
target
cell
unlabel
effector
cell
ie
pbmc
prepar
rpmi
medium
gibco
contain
fb
ps
cell
densiti
cellsml
respect
subsequ
target
cell
dispens
roundbottom
plate
follow
addit
mous
serum
mous
serum
concentr
group
normal
addit
accord
titer
determin
elisa
one
hour
incub
effector
cell
ad
incub
target
cell
three
hour
later
anoth
ad
well
perform
flow
cytometri
cell
death
determin
facsaria
iii
flow
cytomet
use
bd
fac
softwar
bd
bioscienc
percent
cell
death
calcul
softwar
analysi
four
identifi
cell
popul
live
effector
cell
dye
dead
effector
cell
posit
live
target
cell
posit
dead
target
cell
doubl
posit
assay
control
use
defin
cell
popul
includ
target
cell
alon
background
cell
death
target
cell
triton
ad
maximum
cell
death
percent
adcc
calcul
percent
experiment
lysi
percent
spontan
lysi
percent
maximum
lysi
percent
spontan
lysi
percent
spontan
lysi
refer
percent
lysi
infect
cell
effector
absenc
serum
percent
maximum
lysi
refer
percent
lysi
infect
cell
effector
presenc
triton
experi
perform
triplic
repeat
twice
confirm
immunostain
perform
previous
describ
visual
perforin
express
mous
lung
tissu
rat
antimous
perforin
abcam
goat
antirat
alexa
use
primari
secondari
antibodi
respect
imag
acquir
carl
zeiss
lsm
system
rna
extract
revers
transcript
qpcr
perform
previous
describ
brief
total
rna
extract
mous
lung
rneasi
mini
kit
qiagen
revers
transcrib
transcriptor
first
strand
cdna
synthesi
kit
roch
real
time
pcr
perform
use
roch
machin
accord
manufactur
instruct
rel
gene
express
normal
correspond
valu
sequenc
primer
rtqpcr
list
tabl
supplementari
materi
statist
comparison
perform
student
ttest
use
graphpad
prism
differ
consid
statist
signific
p
previou
studi
map
two
put
adcc
epitop
ha
head
region
deplet
andor
clinic
plasma
igg
antibodi
adcc
activ
drop
significantli
suggest
two
epitop
play
potenti
role
elicit
adcc
studi
sought
confirm
function
put
epitop
induct
adcc
activ
use
mous
model
immun
mice
gave
rais
igg
titer
ha
protein
quantifi
elisa
figur
primeboost
immun
strategi
adopt
mice
immun
pb
ha
includ
neg
posit
control
respect
tabl
result
indic
serum
sampl
mice
vaccin
figur
figur
exhibit
strong
dilutiondepend
antibodi
respons
reach
titer
addit
use
ha
coat
antigen
elisa
demonstr
sera
could
bind
fulllength
ha
compar
effici
figur
supplementari
materi
taken
togeth
data
suggest
vaccin
success
result
serum
sampl
could
util
investig
next
adcc
activ
serum
sampl
haimmun
mice
evalu
flow
cytometrybas
adcc
assay
end
hatransfect
cell
label
cellmembran
marker
util
target
cell
adccspecif
antibodi
bind
subsequ
vaccin
mous
serum
ad
bridg
interact
target
cell
pbmc
effector
cell
figur
presenc
adccmedi
antibodi
determin
analyz
cytotox
rate
within
cell
mixtur
contain
target
cell
serum
effector
cell
dead
target
cell
popul
reveal
cell
death
marker
figur
shown
figur
sera
mice
consist
trigger
highest
rate
among
evalu
group
suggest
higher
percentag
cell
lysi
induc
group
comparison
group
percentag
cytotox
normal
use
formula
report
srivastava
et
al
spontan
maximum
cell
cytotox
rate
taken
consider
quantit
sera
mice
elicit
significantli
increas
p
adcc
activ
comparison
pbsvaccin
group
figur
note
though
sera
mice
trigger
subtl
increas
adcc
activ
differ
statist
signific
figur
intriguingli
albeit
ha
contain
epitop
sera
havaccin
group
induc
significantli
elev
cytotox
respons
comparison
pb
control
group
figur
sinc
capabl
induc
adcc
activ
hypothes
mice
could
potenti
protect
elicit
adcc
activ
influenza
viru
challeng
end
inocul
vaccin
mice
pandem
influenza
viru
lethal
mous
model
figur
shown
figur
mice
havaccin
group
posit
control
demonstr
substanti
reduct
viral
load
day
day
postinocul
comparison
pbsvaccin
group
importantli
detect
approxim
one
log
decreas
viral
load
mous
lung
group
comparison
pbsvaccin
group
day
postinocul
signific
differ
could
observ
two
group
day
postviru
challeng
figur
addit
viral
load
lung
mice
notabl
lower
day
compar
day
suggest
adcc
effect
trigger
day
postinocul
figur
parallel
measur
surviv
rate
bodi
weight
chang
mice
shown
figur
mice
havaccin
group
surviv
cours
infect
mice
receiv
pbstreatment
die
indic
viru
challeng
success
unexpectedli
result
demonstr
mice
group
succumb
influenza
viru
infect
significantli
earlier
time
p
postinocul
compar
pbsvaccin
control
group
figur
line
surviv
rate
mice
group
suffer
appar
acceler
weight
lost
start
day
postinocul
comparison
mice
pb
group
although
differ
reach
statist
signific
figur
next
carri
histopatholog
examin
lung
section
virusinfect
mice
use
uninfect
mous
lung
tissu
control
figur
j
observ
show
day
day
mice
havaccin
group
figur
h
exhibit
amelior
alveolar
morpholog
chang
compar
figur
figur
f
pb
figur
b
group
importantli
lung
patholog
score
mice
havaccin
group
day
day
significantli
lower
pbstreat
mice
figur
l
mice
group
suffer
significantli
dramat
interstiti
inflammatori
infiltr
pbstreat
mice
day
figur
result
indic
detriment
lung
damag
mice
possibl
trigger
adcc
might
account
reduc
viral
load
lung
well
earlier
drop
surviv
address
whether
sever
lung
damag
group
could
attribut
adcc
effect
perform
immunofluoresc
stain
visual
express
level
perforin
among
differ
mous
group
perforin
releas
activ
nk
cell
known
marker
adcc
activ
quantit
figur
mice
figur
demonstr
highest
perforin
express
level
lung
section
amongst
three
group
day
post
infect
figur
howev
mrna
express
level
perforin
significantli
differ
across
evalu
group
figur
bind
fc
receptor
fcr
effector
cell
trigger
secret
cytotox
granul
well
antivir
cytokin
chemokin
investig
elev
express
proinflammatori
cytokin
might
contribut
lung
damag
measur
mrna
express
level
repres
cytokin
includ
figur
figur
figur
mous
lung
sampl
result
show
gene
express
three
proinflammatori
cytokin
significantli
enhanc
group
compar
pbstreat
group
figur
line
perforin
protein
express
pattern
figur
togeth
data
suggest
epitop
ha
head
domain
mediat
unfavor
adcc
result
sever
lung
damag
exacerb
mous
mortal
despit
success
control
influenza
viral
load
antibodydepend
cellmedi
cytotox
bridg
innat
adapt
immun
play
import
role
humor
cellular
immun
respons
sinc
adcc
antibodi
known
recogn
wide
rang
viral
protein
lead
lysi
virusinfect
cell
better
understand
adcc
mechan
influenza
viru
infect
facilit
develop
univers
influenza
vaccin
broader
protect
conserv
viral
protein
domain
extracellular
domain
ha
stem
domain
wide
studi
potenti
target
domainbas
univers
influenza
vaccin
jegerlehn
colleagu
demonstr
protect
role
adccmedi
antibodi
depend
fcr
dilillo
et
al
provid
support
influenzaspecif
adcc
antibodi
though
elicit
ha
stem
also
requir
fcr
interact
protect
lethal
influenza
infect
collect
studi
highlight
function
import
fcr
adccmedi
viru
clearanc
side
unexpect
case
report
young
adult
without
prior
exposur
viru
produc
robust
adccmedi
antibodi
respons
upon
infect
viru
strain
individu
even
possess
crossreact
adccmedi
antibodi
toward
avian
strain
absenc
prior
exposur
howev
mechan
antibodi
respons
remain
unclear
date
studi
investig
adcc
effect
two
put
ha
head
epitop
vitro
vivo
data
demonstr
adcc
activ
influenza
viru
infect
vitro
figur
unexpectedli
although
vaccin
decreas
viral
load
mice
figur
induc
exacerb
lung
damag
figur
higher
level
nk
activ
figur
acceler
mous
death
figur
nk
cell
offer
first
line
defens
viru
infect
wide
consid
benefici
host
viral
infect
howev
recent
report
zhou
et
al
reveal
adopt
transfer
nk
cell
influenza
virusinfect
lung
uninfect
lung
result
rapid
weight
loss
increas
mortal
virusinfect
mice
find
line
observ
adcc
exhibit
deleteri
impact
promot
mortal
influenza
viru
infect
healthi
donor
persist
low
level
crossreact
adccmedi
antibodi
crossreact
antibodi
found
individu
absenc
detect
neutral
previou
studi
epitop
identifi
put
region
could
induc
adcc
activ
deplet
antibodi
human
plasma
significantli
decreas
adcc
effect
howev
certain
sampl
appear
dilut
plasma
exhibit
higher
adcc
activ
less
dilut
plasma
use
igg
antibodi
low
concentr
led
higher
adcc
activ
use
igg
antibodi
high
concentr
date
conclus
studi
correl
antibodi
concentr
adcc
activ
neither
optim
concentr
adcc
antibodi
could
protect
viru
infect
elucid
context
demonstr
overwhelm
product
adcc
antibodi
absenc
neutral
might
play
protect
role
influenza
viru
infect
inde
multipl
factor
satur
antibodi
interfer
nonadcc
antibodi
may
contribut
induct
adcc
case
threshold
level
protect
adccmedi
antibodi
investig
studi
variou
adcc
assay
mainli
differ
choic
effector
cell
measur
adcc
activ
report
exampl
studi
use
hatransfect
virusinfect
cell
target
cell
suscept
nk
cellmedi
adcc
incub
sera
healthi
donor
clinic
blood
sampl
case
isol
pbmc
healthi
mice
effector
cell
measur
death
rate
target
cell
presenc
vaccin
mous
sera
figur
time
util
flow
cytometri
quantit
cell
cytotox
provid
effici
precis
way
assess
adcc
respons
figur
importantli
cell
show
low
background
cell
death
absenc
antibodi
figur
suggest
ideal
cell
line
mousespecif
adcc
assay
collect
establish
vitro
adcc
assay
togeth
balcc
mous
model
might
appli
evalu
influenzaspecif
adcc
epitop
experiment
mous
model
invalu
scientif
resourc
allow
comprehens
investig
key
biolog
question
vivo
provid
essenti
platform
studi
mani
human
diseas
wide
acknowledg
mous
human
antibodi
repertoir
share
gener
similar
howev
differ
germlin
antibodi
repertoir
exist
speci
number
matur
b
cell
mice
smaller
human
variat
may
contribut
dissimilar
antibodi
elicit
fragment
human
compar
mice
due
divers
b
cell
antigen
receptor
repertoir
mous
human
model
antibodi
bind
fragment
distinct
host
model
might
potenti
slightli
differ
epitop
altern
may
fundament
differ
murin
human
term
regul
nk
cell
cytotox
granul
secret
surprisingli
distinct
express
pattern
perforin
detect
protein
figur
mrna
figur
level
discrep
might
explain
previou
find
rest
murin
nk
cell
prearm
high
amount
perforin
mrna
rapidli
translat
protein
upon
activ
vitro
vivo
mechan
murin
nk
cell
facilit
better
control
perforin
express
allow
rapid
product
effector
protein
without
need
de
novo
gene
transcript
upon
activ
adcc
effector
cell
produc
variou
cytokin
cytokin
may
repres
one
arm
pathway
stimul
translat
perforin
notabl
human
nk
cell
minim
cytotox
rest
express
littl
perforin
protein
becom
potent
cytotox
cytokin
activ
result
show
significantli
elev
group
compar
pbstreat
group
figur
regard
upregul
cytokin
may
activ
cytotox
perforin
caus
detriment
damag
mous
lung
previou
studi
epitop
locat
ha
head
figur
supplementari
materi
conserv
strain
date
howev
role
ha
head
influenza
viru
infect
adcc
activ
fulli
delin
recent
studi
dilillo
colleagu
report
neutral
antibodi
target
ha
stem
ha
head
capabl
confer
influenzaspecif
adcc
propos
antistem
antibodi
could
bind
correct
conform
ligat
fcr
base
observ
strainspecif
antiha
head
antibodi
unabl
mediat
bind
protect
mice
hand
ha
headinduc
adcc
activ
report
number
group
agreement
find
discrep
observ
might
due
sequenti
structur
variat
among
subtypesstrain
influenza
viru
use
interestingli
although
epitop
locat
ha
head
serum
havaccin
group
trigger
significantli
elev
cytotox
respons
figur
impli
addit
regul
exist
control
adcc
activ
summari
provid
vitro
vivo
evid
verifi
effect
ha
head
epitop
adcc
importantli
data
suggest
adcc
alon
caus
detriment
effect
influenza
viru
infect
rais
concern
use
conserv
nonneutr
region
ha
head
futur
design
univers
influenza
vaccin
fact
headless
ha
recommend
sever
vaccin
design
aim
make
use
adcc
antibodi
data
provid
evid
support
headless
ha
vaccin
design
strategi
zwi
sy
design
perform
experi
kyy
hc
conceiv
studi
lw
perform
molecular
model
zs
mh
dy
myz
bjz
gave
conceptu
advic
technic
support
kmp
cl
jz
hs
conduct
histopatholog
observ
immunostain
zwi
sy
hc
kyy
wrote
manuscript
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
